Whitehawk Therapeutics, Inc. — Director's Dealing 2018

Feb 14, 2018

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: Aerpio Pharmaceuticals, Inc. (ARPO)
CIK: 0001422142
Period of Report: 2017-12-31

Reporting Person: Dalal Anupam (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-12-22	Common Stock	J	7882	$0.00	Disposed	0	Indirect
2017-12-22	Common Stock	J	2269	$0.00	Acquired	2269	Direct

Footnotes

F1: The 7,882 shares of Common Stock are owned by directly by TWHVP SPV, LLC ("TWHVP"). The general partner of TWHVP is Kearny Venture Associates II, LLC ("KVA II"). KVA II has the sole voting and investment control over the shares owned by TWHVP and the Managing Members of KVA II have sole voting and investment control over the shares controlled by KVA II. The Managing Members of KVA II are Caley Castelein, Anupam Dalal and Andrew Jensen. None of the Managing Members of KVA II have individual voting or investment power with respect to such shares and each disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Pursuant to the Limited Liability Company Agreement KVA II made an in-kind distribution to the members on December 22, 2017. KVA II currently owns 0 shares of the Issuer.

F2: Pro rata distribution from Kearny Venture Associates II, LLC., of which the reporting person is a managing member.